Industry
Biotechnology
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 12:01 pm
Portfolio Pulse from Benzinga Newsdesk
April 25, 2024 | 11:24 am
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 11:20 am
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 11:05 am
Portfolio Pulse from Benzinga Newsdesk
April 04, 2024 | 5:47 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 6:04 pm
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 9:10 pm
Portfolio Pulse from totan@benzinga.com
March 07, 2024 | 9:07 pm
Portfolio Pulse from Benzinga Insights
March 07, 2024 | 9:49 am
Portfolio Pulse from Benzinga Insights
March 06, 2024 | 7:02 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.